A phase I study of ambulatory continuous infusion paclitaxel

Anti-Cancer Drugs

Volumn 8, Issue 9, 1997, Pages 823-828

  Skubitz, Keith M ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Chemotherapy; Continuous infusion; paclitaxel; Sarcoma; Taxol

Indexed keywords

DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; STOMATITIS;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0030700784     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199710000-00002     Document Type: Article

References (18)

1. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain memorial award lecture. Cancer Res 1995; 55: 753-60.
2. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
3. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). New Engl J Med 1995; 15: 1004-14.
4. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847.
5. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J Clin Oncol 1994; 12: 1748-53.
6. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-75.
7. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
8. Skubitz KM. Infusional chemotherapy for soft tissue sarcomas. J Infus Chemother 1993; 3: 129-36.
9. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-25.
10. 1, phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4355-61.
11. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Cancer Res 1995; 1: 599-606.
12. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10: 275-8.
13. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer, extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520-4.
14. Chin A, Ramakrishnan RR, Yoshimura NN, Jeong EWS, Nii LJ, DiMeglio LS. Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacother 1994; 28: 35-6.
15. Skubitz KM, Hamdan H, Thompson RC, Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993; 72: 2963-9.
16. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-85.
17. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 1995; 76: 2248-52.
18. Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 1996; 15: 526.